ESR1 and neoplasm: In this population, about 10% of the tumors with co-expression of those receptors were associated with less aggressive tumors, (higher expression of ER and progesterone, earlier clinical stage, lower ki67 and smaller tumor size), so with better outcome in terms of survival [14,24].